(19)
(11) EP 3 507 277 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.03.2021 Bulletin 2021/09

(45) Mention of the grant of the patent:
18.11.2020 Bulletin 2020/47

(21) Application number: 17764971.2

(22) Date of filing: 29.08.2017
(51) International Patent Classification (IPC): 
C07D 265/14(2006.01)
A61P 25/24(2006.01)
 A61K 31/537(2006.01)
(86) International application number:
PCT/US2017/049129
(87) International publication number:
WO 2018/044896 (08.03.2018 Gazette 2018/10)

(54)

HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF DISORDERS

HYDROXYNORKETAMINDERIVATE ZUR BEHANDLUNG VON ERKRANKUNGEN

DÉRIVÉS D'HYDROXYNORKÉTAMINE POUR LE TRAITEMENT DES MALADIES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 31.08.2016 US 201662382132 P

(43) Date of publication of application:
10.07.2019 Bulletin 2019/28

(73) Proprietor: Dart NeuroScience, LLC
Dallas, TX 75219 (US)

(72) Inventors:
  • GOMEZ, Laurent
    Dallas, TX 75219 (US)
  • MASSARI, Mark, Eben
    Texas, TX 75219 (US)

(74) Representative: McGuire, Gillian Margaret 
Carpmaels & Ransford LLP One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A1-2004/045601
   
  • PANOS ZANOS ET AL: "NMDAR inhibition-independent antidepressant actions of ketamine metabolites", NATURE, vol. 533, no. 7604, 4 May 2016 (2016-05-04), pages 481-486, XP55368059, ISSN: 0028-0836, DOI: 10.1038/nature17998 cited in the application
  • MOADDEL R ET AL: "A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome", TALANTA, ELSEVIER, AMSTERDAM, NL, vol. 82, no. 5, 15 October 2010 (2010-10-15), pages 1892-1904, XP027338855, ISSN: 0039-9140 [retrieved on 2010-08-13] cited in the application
  • J. D. ADAMS ET AL: "Studies on the biotransformation of ketamine 1-Identification of metabolites producedin vitro from rat liver microsomal preparations", BIOLOGICAL MASS SPECTROMETRY, vol. 8, no. 11, 1 November 1981 (1981-11-01), pages 527-538, XP55048408, ISSN: 1052-9306, DOI: 10.1002/bms.1200081103
  • PATRICK J. MORRIS ET AL: "-aspartate (NMDA) Receptor Activity of Ketamine Metabolites", ORGANIC LETTERS , 14(23), 6012-6015 CODEN: ORLEF7; ISSN: 1523-7052, vol. 19, no. 17, 22 August 2017 (2017-08-22), pages 4572-4575, XP055410503, ISSN: 1523-7060, DOI: 10.1021/acs.orglett.7b02177
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).